A randomized, patient/evaluator‐blinded, split‐face study to compare the efficacy and safety of polycaprolactone and polynucleotide fillers in the correction of crow's feet: The latest biostimulatory dermal filler for crow's feet. (4th November 2019)

• Record Type: Journal Article
• Authors: Jeong, Guk Jin; Ahn, Ga Ram; Park, Su Jung; Hong, Ji Yeon; Kim, Beom Joon
• Is Part Of: Journal of cosmetic dermatology. Volume 19:Number 7(2020)
• Page Start: 1593
• Page End: 1599
• Publication Date: 2019-11-04
• Subjects: biostimulatory -- crow's feet -- dermal filler -- polycaprolactone -- polynucleotide; Skin -- Diseases -- Treatment -- Periodicals; Lasers in surgery -- Periodicals; Skin -- Pathophysiology -- Periodicals; Surgery, Plastic -- Periodicals; 616.5
• DOI: 10.1111/jocd.13199
• Languages: English
• ISSNs: 1473-2130

Abstract

Abstract: Background: No data on the clinical results and safety profiles of the polycaprolactone (PCL) ‐based dermal filler for crow's feet correction have been published. Aims: This study was designed to compare the efficacy and safety of a novel PCL‐based dermal filler, DLMR01, with that of RJR, a purified polynucleotide dermal filler. Patients/Methods: A total of 30 subjects with symmetric crow's feet of 2‐4 points on the Crow's Feet Grading Scale (CFGS) were enrolled in this randomized, patient/evaluator‐blinded, split‐face study. Each subject was randomized to receive injections of DLMR01 or RJR in their right or left crow's feet. At 4 and 12 weeks, all participants were evaluated via CFGS, Global Aesthetic Improvement Scale (GAIS), and PRIMOS software system. Results: No significant difference in CFGS, GAIS, and R a value was detected between DLMR01 side and RJR at 12 weeks (improvement rate in CFGS from baseline at week 12—DLMR01: 48.28% [14/29], RJR: 41.38% [12/29]). Conclusion: The novel PCL‐based dermal filler DLMR01 shows suitable efficacy and safety, widening the selection possibilities for clinicians and patients in the treatment crow's feet.